Hematopoietic growth factor mimetics: from concept to clinic.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Cytokine & growth factor reviews

• Publication date

  2009-02-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.cytogfr.2009.01.002PMID 19223217
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP.

  2009cited by this paper
• Thrombopoietin and thrombopoietin mimetics in the treatment of thrombocytopenia.

  2009influential reference
• thrombocytopenic patients with chronic ITP Safety and efficacy of long-term treatment with romiplostim in

  2009cited by this paper
• Growth hormone receptor modulators

  2009cited by this paper
• Safety and Efficacy of Long-Term Treatment with Oral Eltrombopag for Chronic Idiopathic Thrombocytopenic Purpura.

  2008cited by this paper
• Erythropoietins: a common mechanism of action.

  2008cited by this paper
• Differential Effects of a Novel Non-Peptidic Thrombopoietin Mimetic on Proliferation and Differentiation of Human CD34+ Progenitor Cells

  2008cited by this paper
• Is there a role for growth hormone therapy in refractory critical illness?

  2008cited by this paper
• Recombinant human growth hormone: rationale for use in the treatment of HIV-associated lipodystrophy.

  2008cited by this paper
• New drugs for familiar therapeutic targets: thrombopoietin receptor agonists and immune thrombocytopenic purpura

  2008cited by this paper
• Oral Eltrombopag for the Long-Term Treatment of Patients with Chronic Idiopathic Thrombocytopenic Purpura: Results of a Phase III, Double- Blind, Placebo-Controlled Study (RAISE)

  2008cited by this paper
• Efficacy and Safety of Repeated Intermittent Treatment with Eltrombopag in Patients with Chronic Idiopathic Thrombocytopenic Purpura.

  2008cited by this paper
• Eltrombopag Is Efficacious in Patients with Refractory Chronic Idiopathic Thrombocytopenic Purpura (ITP) - Data from the EXTEND Study

  2008cited by this paper
• The Potency of Erythropoietin-Mimic Antibodies Correlates Inversely with Affinity

  2008cited by this paper
• Low Immunogenicity to Romiplostim in Clinical Studies with ITP Subjects.

  2008cited by this paper
• Long-Term Safety Profile of Romiplostim in Patients with Chronic Immune Thrombocytopenia (ITP).

  2008cited by this paper
• Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial.

  2008cited by this paper
• CBAP interacts with the un-liganded common β-subunit of the GM-CSF/IL-3/IL-5 receptor and induces apoptosis via mitochondrial dysfunction

  2008cited by this paper
• Eltrombopag Delivers Clinical Benefit in Chronic Idiopathic Thrombocytopenic Purpura (ITP) Patients Not Achieving Platelet Counts ≥50,000/μL - Data from the EXTEND Study.

  2008cited by this paper
• Clinical Characterization of a Novel Oral Thrombopoietin Mimetic LGD-4665 in Healthy Volunteers Demonstrate Safe and Sustained Increases in Platelet Counts with Flexible Dosing Choices for Phase II Trials.

  2008cited by this paper
• Growth hormone use in the treatment of idiopathic short stature.

  2008cited by this paper
• Issues and trends in pediatric growth hormone therapy--an update from the GHMonitor observational registry.

  2008cited by this paper
• Improving Growth in Children with Inflammatory Bowel Disease

  2007cited by this paper
• New agents that stimulate erythropoiesis.

  2007cited by this paper
• Single and Multiple Oral Doses of LGD-4665, a Small Molecule Thrombopoietin Receptor Agonist, Increase Platelet Counts in Healthy Male Subjects

  2007cited by this paper
• New thrombopoietic growth factors.

  2007cited by this paper
• Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist.

  2007cited by this paper
• A ligand-receptor fusion of growth hormone forms a dimer and is a potent long-acting agonist

  2007cited by this paper
• Role of recombinant human growth hormone in HIV-associated wasting and cachexia: pathophysiology and rationale for treatment.

  2007cited by this paper
• Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly.

  2007cited by this paper
• Long-Term Safety and Efficacy of Oral Eltrombopag for the Treatment of Subjects with Idiopathic Thrombocytopenic Purpura (ITP): Preliminary Data from the EXTEND Study.

  2007cited by this paper
• A potent erythropoietin-mimicking human antibody interacts through a novel binding site.

  2007cited by this paper
• Thrombopoietin mimetic agents in the management of immune thrombocytopenic purpura.

  2007cited by this paper
• Early recombinant human growth hormone treatment in glucocorticoid-treated children with juvenile idiopathic arthritis: a 3-year randomized study.

  2007cited by this paper
• Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura.

  2007cited by this paper
• Management of Growth Retardation in Juvenile Idiopathic Arthritis

  2007cited by this paper
• AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP.

  2006influential reference
• A rationally designed agonist antibody fragment that functionally mimics thrombopoietin

  2006cited by this paper
• Strategies to improve plasma half life time of peptide and protein drugs

  2006cited by this paper
• Evaluation of the safety and pharmacodynamics of Hematide, a novel erythropoietic agent, in a phase 1, double-blind, placebo-controlled, dose-escalation study in healthy volunteers.

  2006cited by this paper
• Single and Multiple Oral Doses of AKR-501 (YM477) Increase the Platelet Count in Healthy Volunteers.

  2006cited by this paper
• Domain Subclass Conversion Improved Activity of Anti-Mpl Agonist Antibodies in the Form of Whole IgG.

  2006cited by this paper
• Stimulation of Platelet Production in Healthy Volunteers by a Novel Pegylated Peptide-Based Thrombopoietin (TPO) Receptor Agonist.

  2005cited by this paper
• Hematide™, a Synthetic Peptide-Based Erythropoiesis Stimulating Agent (ESA), Demonstrates Erythropoietic Activity in a Phase 2 Single Dose, Dose Escalating Study in Patients with Chronic Kidney Disease (CKD).

  2005cited by this paper
• Cancer-Related Anemia: Pathogenesis, Prevalence and Treatment

  2005cited by this paper
• Standard of Care for Cancer-Related Anemia: Improving Hemoglobin Levels and Quality of Life

  2005cited by this paper
• CERA (Continuous Erythropoietin Receptor Activator): a new erythropoiesis-stimulating agent for the treatment of anemia.

  2005cited by this paper
• A novel therapeutic approach for thrombocytopenia by minibody agonist of the thrombopoietin receptor.

  2005cited by this paper
• Cancer-Related Anemia: Biological Findings, Clinical Implications and Impact on Quality of Life

  2005cited by this paper
• Epoetin alfa. Clinical evolution of a pleiotropic cytokine.

  2004cited by this paper
• Prevalence and outcomes of anemia in inflammatory bowel disease: a systematic review of the literature.

  2004cited by this paper
• Prevalence and outcomes of anemia in individuals with human immunodeficiency virus: a systematic review of the literature.

  2004cited by this paper
• Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand

  2004cited by this paper
• Chemotherapy‐induced neutropenia

  2004cited by this paper
• Prevalence of anemia in erythropoietin-treated pediatric as compared to adult chronic dialysis patients.

  2004cited by this paper
• Pure red-cell aplasia and epoetin therapy.

  2004cited by this paper
• Species Specificity and Receptor Domain Interaction of a Small Molecule TPO Receptor Agonist.

  2004cited by this paper
• Pure red cell aplasia and anti-erythropoietin antibodies in patients treated with epoetin.

  2003cited by this paper
• It's moving day: factors affecting peripheral blood stem cell mobilization and strategies for improvement [corrected].

  2003cited by this paper
• Severe chronic neutropenia: Treatment and follow‐up of patients in the Severe Chronic Neutropenia International Registry

  2003cited by this paper
• Epitope map for a growth hormone receptor agonist monoclonal antibody, MAb 263.

  2003cited by this paper
• It's moving day: factors affecting peripheral blood stem mobilization and strategies for improvement

  2003cited by this paper
• PRE-dialysis survey on anaemia management.

  2003cited by this paper
• The management of anemia in pediatric peritoneal dialysis patients

  2003cited by this paper
• Recombinant human erythropoietin in pediatric oncology: a review.

  2002cited by this paper
• Identification of a pharmacophore for thrombopoietic activity of small, non-peptidyl molecules. 2. Rational design of naphtho[1,2-d]imidazole thrombopoietin mimics.

  2002cited by this paper
• Activation of Erythropoietin Receptor through a Novel Extracellular Binding Site.

  2002cited by this paper
• Activation of erythropoietin receptor through a novel extracellular binding site.

  2002cited by this paper
• Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor.

  2002cited by this paper
• Functional cross‐talk between cytokine receptors revealed by activating mutations in the extracellular domain of the β‐subunit of the GM‐CSF receptor

  2002cited by this paper
• Recombinant human thrombopoietin: basic biology and evaluation of clinical studies.

  2002cited by this paper
• Structure of the complete extracellular domain of the common beta subunit of the human GM-CSF, IL-3, and IL-5 receptors reveals a novel dimer configuration.

  2001cited by this paper
• Thrombocytopenia caused by the development of antibodies to thrombopoietin.

  2001cited by this paper
• Hydrazinonaphthalene and azonaphthalene thrombopoietin mimics are nonpeptidyl promoters of megakaryocytopoiesis.

  2001cited by this paper
• Crystallographic evidence for preformed dimers of erythropoietin receptor before ligand activation.

  1999cited by this paper
• Human dendritic cells express the thrombopoietin receptor, c‐Mpl

  1999cited by this paper
• Small molecule cytokine mimetics.

  1999cited by this paper
• An Erythropoietin Fusion Protein Comprised of Identical Repeating Domains Exhibits Enhanced Biological Properties*

  1999cited by this paper
• Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients.

  1999cited by this paper
• Efficiency of signalling through cytokine receptors depends critically on receptor orientation

  1998cited by this paper
• Activation of Chimeric and Full-length Growth Hormone Receptors by Growth Hormone Receptor Monoclonal Antibodies

  1998cited by this paper
• Activating mutations in cytokine receptors: implications for receptor function and role in disease.

  1997cited by this paper
• Erythropoietin induces tyrosine phosphorylation of the interleukin-3 receptor beta subunit (betaIL3) and recruitment of Stat5 to possible Stat5-docking sites in betaIL3.

  1997cited by this paper
• Peptide agonist of the thrombopoietin receptor as potent as the natural cytokine.

  1997cited by this paper
• Erythropoietin Induces Tyrosine Phosphorylation of the Interleukin-3 Receptor β Subunit (βIL3 ) and Recruitment of Stat5 to Possible Stat5-Docking Sites in βIL3

  1997cited by this paper
• Increased potency of an erythropoietin peptide mimetic through covalent dimerization

  1997cited by this paper
• Functional Mimicry of a Protein Hormone by a Peptide Agonist: The EPO Receptor Complex at 2.8 Å

  1996cited by this paper
• Small Peptides as Potent Mimetics of the Protein Hormone Erythropoietin

  1996cited by this paper
• Erythropoietin induces tyrosine phosphorylation of the beta chain of the GM-CSF receptor.

  1995cited by this paper
• Point mutations within a dimer interface homology domain of c‐Mpl induce constitutive receptor activity and tumorigenicity.

  1995cited by this paper

• Engineering synthetic signaling receptors to enable erythropoietin-free erythropoiesis

  2025cites this paper
• Selection of a Full Agonist Combinatorial Antibody that Rescues Leptin Deficiency In Vivo

  2020cites this paper
• Nanomaterials for Regenerative Medicine

  2019cites this paper
• Title Early Development of Definitive Erythroblasts from Human Pluripotent Stem Cells Defined by Expression of Glycophorin A / CD 235 a , CD 34 , and CD 36

  2019cites this paper
• Coating Matters: Review on Colloidal Stability of Nanoparticles with Biocompatible Coatings in Biological Media, Living Cells and 
Organisms

  2018cites this paper
• A novel therapeutic strategy targeting multiple members of the γc-family cytokines; principles, relevance and potentially broad clinical applications.

  2017cites this paper
• Early Development of Definitive Erythroblasts from Human Pluripotent Stem Cells Defined by Expression of Glycophorin A/CD235a, CD34, and CD36

  2016cites this paper
• A novel molecular probe 131I-K237 targeting tumor angiogenesis in human prostate cancer xenografts.

  2015cites this paper
• Derivation of Mature Erythrocytes from Human Pluripotent Stem Cells by Coculture with Murine Fetal Stromal Cells

  2015cites this paper
• Large‐scale production of red blood cells from stem cells: What are the technical challenges ahead?

  2014cites this paper
• Thrombopoietin improved ventricular function and regulated remodeling genes in a rat model of myocardial infarction.

  2013cites this paper
• Subchronic safety evaluation of EPO-018B, a pegylated peptidic erythropoiesis stimulating agent, after 5-week subcutaneous injection in Cynomolgus monkeys and Sprague-Dawley rats.

  2013cites this paper
• The Utilization of Perforated Bioinert Chambers to Generate an In Vivo Isolated Space for Tissue Engineering Involving Chondrocytes, Mesenchymal Stem Cells, and Fibroblasts

  2013cites this paper
• How Far are Stem-Cell-Derived Erythrocytes from the Clinical Arena?

  2013cites this paper
• Dynamic Ligand Modulation of EPO Receptor Pools, and Dysregulation by Polycythemia-Associated EPOR Alleles

  2012cites this paper
• Revisiting use of growth factors in myelodysplastic syndromes.

  2012influential citation
• Cell microencapsulation for therapeutic purposes: towards greater control over biocompatibility

  2012cites this paper
• Principal signalling complexes in haematopoiesis: structural aspects and mimetic discovery.

  2011cites this paper
• Effects of Copper on Proliferation and Autocrine Secretion of Insulin-Like Growth Factor-1 (IGF-1) and IGF-Binding Protein-3 (IGFBP-3) in Chondrocytes from Newborn Pigs In Vitro

  2011cites this paper
• Emerging technologies in the delivery of erythropoietin for therapeutics

  2011cites this paper
• Thrombopoietin protects against doxorubicin‐induced cardiomyopathy, improves cardiac function, and reversely alters specific signalling networks

  2011cites this paper
• Synthesis, characterisation, and mass spectrometric detection of a pegylated EPO-mimetic peptide for sports drug testing purposes.

  2011cites this paper
• Finding small molecule ligand for affinity purification of human coagulation factor VIII by means of the in silico molecular docking

  2011cites this paper
• Recent developments in doping testing for erythropoietin

  2011cites this paper
• Manufactured RBC--rivers of blood, or an oasis in the desert?

  2011cites this paper
• Peptidic tumor targeting agents: the road from phage display peptide selections to clinical applications.

  2010cites this paper
• Pharmacotherapy of Chronic Immune Thrombocytopenic Purpura (ITP) with Romiplostim

  2010cites this paper
• Erythropoietin receptor response circuits

  2010cites this paper
• A review of immune thrombocytopenic purpura: focus on the novel thrombopoietin agonists

  2010cites this paper
• Study on biodistribution and imaging of radioiodinated arginine-arginine-leucine peptide in nude mice bearing human prostate carcinoma

  2010cites this paper
• Blood cell manufacture: current methods and future challenges.

  2009cites this paper